AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10400847
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) 100 microgram once daily
Trial: 10400847
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray (MFNS) 200 microgram once daily
Trial: 10400847
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 84 microgram twice daily (168 microgram/day)
Trial: 17503885
Drug: Trimetazidine 20
RxNorm normalized name: trimetazidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 20 mg every 8 hours, starting 15 days before PCI and continuing for 3 months after the procedure.
Trial: 15731325
Drug: Subarachnoid block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid block with 2.5 mg hyperbaric bupivacaine + 25 mug fentanyl + 1 mL 10% glucose (Group S)
Trial: 15731325
Drug: Pudendal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pudendal nerve block with 7 mL 2% mepivacaine (Group P)
Trial: 7814237
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg vitamin C per day
Trial: 2550176
Drug: nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nedocromil sodium (2 x 2 mg puffs twice a day)
Trial: 368333
Drug: Clonidine (Dixarit)
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine (Dixarit) at a dose of up to 0.15 mg daily
Trial: 27799203
Drug: ABX464 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 (50 mg) under fed conditions
Trial: 27799203
Drug: ABX464 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 (50 mg) under fasted conditions
Trial: 27799203
Drug: ABX464 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 (50 mg)
Trial: 26761561
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily physical activity (usual group; UG)
Trial: 21504485
Drug: CF101 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 (2 mg)
Trial: 19910566
Drug: bicarbonate-buffered peritoneal
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bicarbonate-buffered peritoneal dialysis solution (bicPDF)
Trial: 8150100
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg two times per day for 9 months)
Trial: 8150100
Drug: Spironolactone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100 mg for 9 months)
Trial: 29578097
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HPV vaccine (1-180 days)
Trial: 29578097
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of HPV vaccine (1-60-180 days)
Trial: 28688643
Drug: Lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patch applied around the surgical wound
Trial: 28688643
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with adhesive sides of the lidocaine patches shielded with waterproof films
Trial: 22612364
Drug: 0.3 mg/mL
RxNorm normalized name: menthol 0.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/mL rhPDGF-BB
Trial: 22612364
Drug: 1.0 mg/mL
RxNorm normalized name: P.T.E.-4, 1 mcg-0.1 mg-0.025 mg-1.0 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/mL rhPDGF-BB
Trial: 20979997
Drug: Recombinant luteinizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant luteinizing hormone (LH) luteal supplementation
Trial: 18364502
Drug: HPV testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV testing (cutoff of 1 pg/mL)
Trial: 18364502
Drug: HPV testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV testing (cutoff of 2 pg/mL)
Trial: 16293958
Drug: Nebulized flunisolide
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized flunisolide (1 mg) + salbutamol/ipratropium bromide (1,875/375 microg) b.i.d.
Trial: 10080566
Drug: D-cycloserine 100
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine 100 mg/day
Trial: 7744141
Drug: Zoladex 10.8-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex 10.8-mg depot administered every 12 weeks
Trial: 7744141
Drug: Zoladex 3.6-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex 3.6-mg depot administered every 28 days
Trial: 2405137
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (6 months) before the initiation of vitamin D therapy
Trial: 2405137
Drug: Serum concentrations
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum concentrations of alkaline phosphatase, parathyroid hormone, and bicarbonate
Trial: 19819688
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (Group A)
Trial: 19819688
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prophylaxis (Group B)
Trial: 31977628
Drug: 0.04 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 μg/kg/min norepinephrine infusion
Trial: 31977628
Drug: 0.05 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 μg/kg/min norepinephrine infusion
Trial: 31977628
Drug: 0.06 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 μg/kg/min norepinephrine infusion
Trial: 31977628
Drug: 0.07 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 μg/kg/min norepinephrine infusion
Trial: 31977628
Drug: 0 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 μg/kg/min norepinephrine infusion (control)
Trial: 30477937
Drug: Regorafenib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (160 mg/day for 21 of 28 days)
Trial: 28342829
Drug: Intensive peer
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive peer mentoring (weekly meetings during inpatient stay and weekly contact for 90 days postdischarge)
Trial: 17387223
Drug: Yttrium-90 ibritumomab
RxNorm normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yttrium-90 ibritumomab tiuxetan (single dose)
Trial: 12808776
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oxytocin (starting at 10 mIU/minute)
Trial: 12808776
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oxytocin (starting at 4 mIU/minute)
Trial: 12808776
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (high and low dose)
Trial: 17012095
Drug: Psycho-education (PE)
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-education (PE) program (four 60-minute weekly manual driven sessions)
Trial: 14668771
Drug: SPECT imaging
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECT imaging after sublingual administration of 10 mg isosorbide dinitrate
Trial: 14668771
Drug: SPECT imaging
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECT imaging after nitrate administration
Trial: 1279279
Drug: Isoprenaline (ISO)
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprenaline (ISO) 1 microgram/min via intravenous infusion
Trial: 1279279
Drug: Mepindolol TSD
RxNorm normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepindolol TSD patches
Trial: 1279279
Drug: Placebo TSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo TSD patches
Trial: 3905070
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefoxitin i.v. in the preoperative period
Trial: 3905070
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefoxitin i.v. in the preoperative period + T tube suction drainage
Trial: 30517731
Drug: Mediterranean-Style Eating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean-Style Eating Pattern with 500 g/wk of lean unprocessed red meat (Med-Red Pattern)
Trial: 30517731
Drug: Mediterranean-Style Eating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean-Style Eating Pattern with 200 g/wk of lean unprocessed red meat (Med-Control Pattern)
Trial: 26947568
Drug: Outpatient protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient protocol for weaning from tube to oral feeding (6-month program)
Trial: 24882900
Drug: Eszopiclone (ESZ)
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eszopiclone (ESZ) 3 mg plus naproxen 500 mg BID
Trial: 24882900
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus naproxen 500 mg BID
Trial: 18319360
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg immediate release 3 times daily for 7 days
Trial: 18319360
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg extended release once daily for 7 days
Trial: 18319360
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg propiverine intravenously
Trial: 18319360
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg immediate release administered at night
Trial: 15703362
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet containing lamivudine, stavudine, and nevirapine (treatment A)
Trial: 15703362
Drug: Separate marketed
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate marketed tablets administered simultaneously (treatment B)
Trial: 15703362
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet (treatment A)
Trial: 15703362
Drug: Separate marketed
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate marketed tablets (treatment B)
Trial: 11168457
Drug: Protectamin (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protectamin (45 g daily for 2 weeks)
Trial: 11990003
Drug: Protectamin (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protectamin (45 g daily for 6 months)
Trial: 11168457
Drug: Immunocal (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunocal (45 g daily for 2 weeks)
Trial: 10418924
Drug: 1 microg
RxNorm normalized name: Alpha 1 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microg dose of PncT
Trial: 10418924
Drug: 3 microg
RxNorm normalized name: Calcitriol 3 microgram/g cutaneous ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 microg dose of PncT
Trial: 10418924
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg dose of PncT
Trial: 10418924
Drug: Booster response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Booster response to three vaccine serotypes in the group primed with the lowest dose of conjugate vaccine (1 microg)
Trial: 2147884
Drug: L-dropropizine
RxNorm normalized name: dropropizine
DrugBank: Dropropizine (DB13785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dropropizine
Trial: 10442379
Drug: Endocrine-only therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine-only therapy
Trial: 18033754
Drug: Torcetrapib added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Torcetrapib added to atorvastatin (4 weeks)
Trial: 10577754
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of morphine and naloxone
Trial: 6870623
Drug: Aminocaproic acid
RxNorm normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminocaproic acid (100 mg/kg every four hours for five days, max 30 g daily)
Trial: 27825616
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg orally daily
Trial: 26397228
Drug: Sorafenib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib treatment with low LDH serum levels
Trial: 26397228
Drug: Sorafenib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib treatment with high LDH serum levels
Trial: 26397228
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without sorafenib
Trial: 28611340
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) infusion for 72 hours
Trial: 19524577
Drug: Placebo (dextrose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dextrose) infusion for 72 hours
Trial: 15213040
Drug: Dietary inorganic
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary inorganic sulfur intake (0.17-0.27 g S/d)
Trial: 15213040
Drug: Average protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average protein intake (72 g/d)
Trial: 15213040
Drug: Typical UK
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical UK intakes of inorganic sulfur (0.25 g/d)
Trial: 10971248
Drug: Heparin-coated group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated group (n = 15; Quadrox Bioline oxygenator/reservoir and Carmeda BioMedicus BP-80 centrifugal pump)
Trial: 10971248
Drug: Non-heparin-coated group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-heparin-coated group (n = 12; uncoated oxygenator, centrifugal pump, tubing, and filter set)
Trial: 10971248
Drug: Heparin-coated group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated group (n = 15)
Trial: 10971248
Drug: Non-heparin-coated group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-heparin-coated group (n = 12)
Trial: 1520018
Drug: KabiVial 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KabiVial 16 IU/ml combined with an Auto Injector
Trial: 1520018
Drug: KabiPen 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KabiPen 16 IU/ml
Trial: 15870187
Drug: Ocinaplon (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocinaplon (total daily dose of 180-240 mg)
Trial: 12676074
Drug: Ben 10
RxNorm normalized name: butamben 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ben 10 mg/d, po
Trial: 12676074
Drug: Val 80
RxNorm normalized name: Val
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Val 80 mg/d, po
Trial: 12676074
Drug: Val 80
RxNorm normalized name: Val
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Val 80 mg/d + Ben 10 mg/d, po
Trial: 1829372
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg carbidopa every 8 h during ANP infusion
Trial: 6421344
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug regimen (sodium fluoride, vitamin D, calcium gluconate, fluoxymesterone)
Trial: 27253829
Drug: MDMA administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MDMA administration in CYP2D6 poor metabolizers
Trial: 22072272
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment 3×/wk during radiotherapy
Trial: 20466163
Drug: Premix insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premix insulin (biphasic insulin aspart 30 [NovoMix 30])
Trial: 20466163
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin (insulin detemir [Levemir])
Trial: 20466163
Drug: Meal-time insulin
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal-time insulin (insulin aspart [NovoRapid])
Trial: 20466163
Drug: All insulin
RxNorm normalized name: Small Insulin Syringe 1cc 31g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All insulin analogs
Trial: 17676985
Drug: Chemoprophylaxis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoprophylaxis with Deltaprim (3.125 mg of pyrimethamine plus 25 mg of dapsone)
Trial: 11329231
Drug: Troglitazone, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone, 400 mg/d
Trial: 9291302
Drug: Inactivated varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated varicella vaccine (single dose at 1 month after transplantation)
Trial: 9291302
Drug: Inactivated varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated varicella vaccine (three doses at 1, 2, and 3 months after transplantation)
Trial: 9291302
Drug: Inactivated varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated varicella vaccine (three doses)
Trial: 8409112
Drug: ONO-1078, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-1078, 150 mg capsule, administered every 12 hours for 1 week
Trial: 8409112
Drug: Placebo, inactive,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, inactive, administered every 12 hours for 1 week
Trial: 3516203
Drug: Ibuprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1200 mg daily)
Trial: 29444611
Drug: Goreisan (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goreisan (7.5 g daily for 12 weeks)
Trial: 27554053
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patch (applied 10 hours previously)
Trial: 22549090
Drug: GTU(®)-Multi-HIVB vaccine
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTU(®)-Multi-HIVB vaccine (1mg/dose IM at 0, 4, 12 weeks, boosted at 76 and 80 weeks with 2mg/dose)
Trial: 17276548
Drug: Oral indomethacin/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral indomethacin/acetaminophen combination therapy
Trial: 17276548
Drug: Oral prednisolone/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone/acetaminophen combination therapy
Trial: 16198660
Drug: BAY 59‐‐7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59‐‐7939 (1.25‐‐80 mg)
Trial: 16198660
Drug: BAY 59‐‐7939
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 59‐‐7939 (5‐mg tablet and oral solution)
Trial: 12189361
Drug: Valganciclovir (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir (900 mg oral administration)
Trial: 8849180
Drug: Doxycycline plus
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline plus ketoprofen (doxycycline 100 mg twice daily for 10 days plus ketoprofen 200 mg daily for 10 days)
Trial: 8849180
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice daily for 10 days)
Trial: 21733319
Drug: Pistachio nuts
RxNorm normalized name: Pistachio nuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistachio nuts (0, 42, and 84 g/d)
Trial: 21148614
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg) once daily
Trial: 15780846
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg Delta‐9‐THC
Trial: 15780846
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg Delta‐9‐THC
Trial: 2255839
Drug: Ivermectin 200
RxNorm normalized name: ivermectin 200 ug / praziquantel 1.5 mg ORAL PASTE [Equimax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 200 mcg/kg
Trial: 1996738
Drug: Ivermectin 400
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 400 mcg/kg (200 mcg/kg per day for 2 days)